MYELOPROLIFERATIVE NEOPLASMS
Clinical trials for MYELOPROLIFERATIVE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASMS trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to tame deadly transplant complication
Disease control CompletedThis study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 22, 2026 12:00 UTC
-
New pill for rare blood cancers shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
Scientists uncover immune clues to prevent transplant complications
Knowledge-focused CompletedThis study looked at how certain immune cells (regulatory and effector T cells) are involved in graft-versus-host disease (GVHD), a common complication after a stem cell transplant from a donor. Researchers analyzed blood and tissue samples from 146 patients and their family dono…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Sponsor: Asan Medical Center • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:54 UTC